C2N Diagnostics launches new assay for Alzheimer’s disease

By The Science Advisory Board staff writers

May 19, 2022 -- C2N Diagnostics debuted a high resolution mass spectrometry-based plasma tau multianalyte assay (p-tau MAA) for research use only that can advance understanding of Alzheimer’s disease.

The assay uses a small sample of blood to measure different phosphorylated and nonphosphorylated forms of the tau protein, including those at the tau217 and tau181 sites. The assay builds on research demonstrating that interactions among abnormal tau and beta-amyloid proteins, as well as several other factors, play a role in Alzheimer's-related brain changes.

Researchers can now evaluate and characterize p-tau MAA's ability to identify Alzheimer's pathology at the early stages of Alzheimer's disease, C2N said.

Copyright © 2022 scienceboard.net

Microscopy and Microanalysis Meeting
July 31 - August 4
Portland, Oregon United States
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter